All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Melanotan II nasal spray: tanning hack or serious gamble?

Stan milsom

TikTok creator

124.5K viewsWatch on TikTok→

Quick answer

Melanotan II is a synthetic melanocortin receptor agonist with documented pigmentation effects in small clinical trials, but it carries a side-effect profile including nausea, cardiovascular changes, and potential dermatological risks that the creator does not address. The video promotes concurrent use with UV tanning beds, a practice that combines two independent risk factors for skin cancer without any safety framing. MT2 holds no regulatory approval for human use in any major jurisdiction, and nasal spray delivery adds bioavailability uncertainty not covered in the available clinical literature.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @stanmilsom1 actually say?

The creator laid out a two-phase protocol for melanotan II (MT2) nasal spray: a "loading phase" of "three to four sprays daily" paired with UV exposure, followed by a maintenance phase of roughly one spray per nostril, three to five times a week. The goal, in their words, is to "get a nice bit of a base tan going on" and then hold that colour over time.

To be clear, this is unsolicited dosing guidance for an unlicensed peptide being sold informally. The creator is not a clinician. They are describing personal use in a casual, first-person style, which does not make it medical advice, but does make it influential given 124,500 views.

Does the science back this up?

Partly, but with serious caveats the video skips entirely. The mechanism is real: MT2 (melanotan II) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that binds melanocortin receptors, particularly MC1R, to stimulate melanogenesis. UV exposure does potentiate the effect.

A 1998 study by Dorr et al. published in the Journal of Clinical Endocrinology and Metabolism confirmed that melanotan II increases pigmentation and that UV light enhances that response. So the creator is not inventing the biology. However, the same study documented a significant side-effect profile including nausea, facial flushing, spontaneous erections, and fatigue, none of which gets a single mention in this video. A 2021 review by Lim et al. in British Journal of Dermatology flagged case reports of melanoma change in existing nevi associated with melanotan use, which is arguably the most important thing anyone considering this peptide should know.

What did they get wrong (or right)?

Credit where it is due: the phased approach, loading then maintenance, loosely mirrors how some researchers have structured melanotan II administration, and the logic of needing UV activation is mechanistically sound. The creator is not completely fabricating things.

What they got wrong is everything they left out. Nasal bioavailability of peptides like MT2 is inconsistent and poorly characterised compared to subcutaneous injection, the route used in most clinical studies. Advising "a couple of sunbeds" as UV activation is particularly reckless given that the WHO classified tanning beds as Group 1 carcinogens in 2009 (Boniol et al., BMJ, 2012). Combining an unregulated melanocortin agonist with UV exposure from a tanning bed is not an optimisation protocol. It is layering two separate skin cancer risk factors on top of each other. The video also gives no acknowledgement that MT2 is not approved by the FDA, MHRA, or EMA, and is not legal for human use in many jurisdictions.

What should you actually know?

MT2 is a research peptide with real pharmacological activity, not a supplement. That means real effects and real risks. The spontaneous erection side effect alone has been documented repeatedly in the literature, including by Wessells et al. in a 1998 Urology study. There are also documented cases of hypertension, rhabdomyolysis, and concerning mole changes in users.

Nasal spray formulations add another layer of uncertainty. Most of the published human data on MT2 used subcutaneous delivery. Transmucosal absorption through the nasal mucosa varies based on formulation, pH, and individual anatomy. Dose consistency from a nasal spray is simply not the same as from a measured injection, which means the "loading phase" arithmetic the creator describes is not reliably transferable from person to person.

  • MT2 is not approved for cosmetic or medical use in the UK, US, EU, or Australia.
  • Combining MT2 with tanning bed UV is not supported by any clinical safety data.
  • Anyone noticing mole changes while using melanotan products should see a dermatologist promptly.
  • Nasal bioavailability data for MT2 specifically is limited and not well validated in peer-reviewed literature.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Melanotan II nasal spray: tanning hack or serious gamble?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Melanotan II nasal spray: tanning hack or serious gamble? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

Melanotan II is a synthetic melanocortin receptor agonist with documented pigmentation effects in small clinical trials, but it carries a side-effect profile including nausea, cardiovascular changes, and potential dermatological risks that the creator does not address.

FormBlends verdict

Melanotan II is a synthetic melanocortin receptor agonist with documented pigmentation effects in small clinical trials, but it carries a side-effect profile including nausea, cardiovascular changes, and potential dermatological risks that the creator does not address. The video promotes concurrent use with UV tanning beds, a practice that combines two independent risk factors for skin cancer without any safety framing. MT2 holds no regulatory approval for human use in any major jurisdiction, and nasal spray delivery adds bioavailability uncertainty not covered in the available clinical literature.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Melanotan II is a synthetic melanocortin receptor agonist with documented pigmentation effects in small clinical trials, but it carries a side-effect profile including nausea, cardiovascular changes, and potential dermatological risks that the creator does not address. The video promotes concurrent use with UV tanning beds, a practice that combines two independent risk factors for skin cancer without any safety framing. MT2 holds no regulatory approval for human use in any major jurisdiction, and nasal spray delivery adds bioavailability uncertainty not covered in the available clinical literature.
  • MT2 is a synthetic melanocortin receptor agonist. It has real pharmacological effects but holds zero regulatory approval for human cosmetic or medical use in the US, UK, EU, or Australia.
  • Dorr et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed MT2 increases pigmentation with UV, but also documented nausea, flushing, and spontaneous erections as side effects. The video mentions none of these.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • MT2 is a synthetic melanocortin receptor agonist. It has real pharmacological effects but holds zero regulatory approval for human cosmetic or medical use in the US, UK, EU, or Australia.
  • Dorr et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed MT2 increases pigmentation with UV, but also documented nausea, flushing, and spontaneous erections as side effects. The video mentions none of these.
  • Tanning beds are classified as Group 1 carcinogens by the WHO. Combining them with an unregulated melanocortin agonist is not optimisation. It is stacking two unvalidated skin cancer risk factors.
  • Nasal spray bioavailability for peptides is inconsistent and not validated against subcutaneous delivery. The dosing arithmetic described in the video cannot be reliably applied across different people or products.
  • Lim et al. (2021, British Journal of Dermatology) reviewed case reports linking melanotan use to atypical mole changes. Anyone using MT2 who notices changes in existing moles should seek dermatology review promptly.
  • The 'loading then maintenance' framing is not drawn from any published clinical protocol for intranasal MT2. It is personal anecdote presented as methodology, and should be treated as such.
  • FormBlends does not endorse, prescribe, or recommend MT2 in any form. This fact-check is for informational purposes and does not constitute medical advice.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Stan milsom · TikTok creator

124.5K views on this video

Save this #mt2 #nasalspray #tanning #tan #peptide

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Stan milsom, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.